【摘要】 由于缺乏分子生物学标志物,急性呼吸窘迫综合征(ARDS)的早期诊断标准一直存在争议,即便2012年柏林新诊断标准对ARDS进行分层诊断,但临床上多是患者发生缺氧症状后才知晓ARDS的发生,动前迫切需要寻找ARDS相关生物学标志物,以便能够早期预警ARDS的发生。本文通过回顾相关文献,阐述肺Clara细胞蛋白16在临床疾病的研究进展,探讨其抗炎、抗纤维化、抗肿瘤及清除自由基等临床应用价值。更多还原

【Abstract】 There have always been controversies over the early diagnosis standards of acute respiratory distress syndrome(ARDS) since lacking of specific molecular biomarkers.Although the, Berlin Definition developed in 2012 proposed 3 categories of ARDS,most of the incidence of ARDS was clinically identified only after hypoxemia happened.So far,there is an urgent need to explore biomarkers of ARDS so that the occurrence of ARDS can be identified as early as possible.This review is focused on the research progresses of Clara cell protein 16 in related diseases,which mainly based on its anti inflammatory,anti- fibrosis,antituvmorigenesis effects and the ability in scavenging free radicals.更多还原